Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

SIMPLE SUMMARY: Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have been established to date. Previous comprehensive...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancers (Basel)
Prif Awduron: Wiele, Andrew J., Surasi, Devaki Shilpa, Rao, Priya, Sircar, Kanishka, Su, Xiaoping, Bathala, Tharakeswara K., Shah, Amishi Y., Jonasch, Eric, Cataldo, Vince D., Genovese, Giannicola, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Msaouel, Pavlos
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://ncbi.nlm.nih.gov/pubmed/33946504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092170
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg